bpc-157 muscle healing study Regeneration or Risk? A Narrative Review of for Musculoskeletal Stable Gastric Pentadecapeptide BPC 157

VEGF Upregulation: The Core Angiogenic Mechanism Vascular endothelial growth factor (VEGF) is the primary driver of new blood vessel formation, and BPC-157 robustly increases its expression

The Muscle Loss Myth: Its Not the Drug, Its the Protocol Lets clarify something critical: muscle loss during GLP-1 therapy is not an inevitable side effect

An important clarification: while the parent protein BPC exists naturally in gastric juice, the specific fragment BPC-157 as used therapeutically is synthesized in a laboratory

Typically 5 mg and 10 mg lyophilised vials

It represents the biologically active fragment of the larger endogenous Body Protection Compound (BPC, MW ~40,000 Da), the smallest sequence retaining BPCs full biological activity profile